Skip to main content
Premium Trial:

Request an Annual Quote

Dx Focus: Meridian Bioscience Ends Beta Trials for CT, NG Assays

Premium

Meridian Bioscience said this week that it has completed beta trials for two new Illumigene molecular amplification tests.

The two new assays, which are based on loop-mediated isothermal amplification, are designed to detect DNA from Chlamydia trachomatis and Neisseria gonorrhoeae from both swab and urine samples. The assays will also for the first time incorporate Meridian's nucleic acid preparation device, which further simplifies the test procedure, as it does not require excessive sample manipulations such as centrifugation or washing; and takes only five minutes to process a sample, Meridian said.

In the beta trial, Meridian tested the performance of the new assays against two undisclosed market-leading molecular platforms on a statistically significant cohort of symptomatic patients. The trials were successful and satisfied the design criteria for both assays, Meridian said. Total test time, from specimen to results, was approximately one hour on the Illumipro-10 Integrated Incubator/Reader.

Meridian said that it expects clinical trials in support of regulatory submission to begin later in its second fiscal quarter, which begins on Jan. 1, and completed later in its fiscal third quarter.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.